We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UNVR:IDXPT Unilever Indonesia Tbk Analysis

Data as of 2026-05-22 - not real-time

IDR 1,765.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

UNVR trades around IDR 1,765, notably above the DCF‑derived fair value of IDR 1,535, signaling a potential overvaluation despite an attractive 7.59% dividend yield. The stock sits below its 20‑day (1,705) and 50‑day (1,817) SMAs, with a bearish trend direction and a neutral RSI of 48.9, while the MACD histogram remains positive, hinting at a short‑term bullish divergence that may not be enough to offset the broader downtrend. High 30‑day volatility (~49%) and decreasing volume add pressure, and the market sentiment index is in "Extreme Greed," suggesting speculative buying may be inflating the price.
Fundamentally, UNVR boasts a robust ROE of 74%, solid cash generation (free cash flow > IDR 3.6 trn), and a defensive consumer‑goods positioning that cushions earnings. However, the payout ratio exceeds 100% (138%), raising concerns about dividend sustainability. Low beta (~0.2) indicates limited systematic risk, but the company’s single‑country exposure and emerging‑market dynamics introduce moderate geographic and regulatory risks. Overall, the stock appears overvalued in the near term but offers long‑term upside if valuation normalizes and dividend policy stabilizes.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price above DCF fair value
  • Bearish technical positioning relative to SMAs
  • Unsustainable dividend payout ratio

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong cash flow and high ROE
  • Defensive consumer‑defensive sector
  • Potential correction toward fair value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Market‑leading brand portfolio and pricing power
  • Consistently high profitability margins
  • Long‑term dividend yield attractiveness if payout normalizes

Key Metrics & Analysis

Financial Health

Revenue Growth2.80%
Profit Margin26.56%
P/E Ratio18.2
ROE74.29%
ROA15.60%
Debt/Equity9.03
P/B Ratio15.0
Op. Cash FlowIDR3943.3B
Free Cash FlowIDR3644.3B

Technical Analysis

TrendBearish
RSI48.9
SupportIDR 1,485.00
ResistanceIDR 1,855.00
MA 20IDR 1,705.25
MA 50IDR 1,816.90
MA 200IDR 2,087.65
MACDBullish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Fair ValueIDR 1,535.70
Target PriceIDR 2,265.00
Upside/Downside28.33%
GradeOvervalued
TypeValue
Dividend Yield7.59%

Risk Assessment

Beta0.25
Volatility49.33%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.